BRPI0506939A - derivados de indolilmaleimida como inibidores de pkc - Google Patents

derivados de indolilmaleimida como inibidores de pkc

Info

Publication number
BRPI0506939A
BRPI0506939A BRPI0506939-4A BRPI0506939A BRPI0506939A BR PI0506939 A BRPI0506939 A BR PI0506939A BR PI0506939 A BRPI0506939 A BR PI0506939A BR PI0506939 A BRPI0506939 A BR PI0506939A
Authority
BR
Brazil
Prior art keywords
pkc inhibitors
indolylmaleimide derivatives
pkc
indolylmaleimide
derivatives
Prior art date
Application number
BRPI0506939-4A
Other languages
English (en)
Inventor
Maurice Van Eis
Juergen Wagner
Peter Von Matt
Jean-Pierre Evenou
Walter Schuler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0401090A external-priority patent/GB0401090D0/en
Priority claimed from GB0401089A external-priority patent/GB0401089D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0506939A publication Critical patent/BRPI0506939A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

DERIVADOS DE INDOLILMALEIMIDA COMO INIBIDORES DE PKC. A presente invenção refere-se a inibidores de PKC os quais são capazes de seletivamente inibir, por exemplo, a e opcionalmente <sym>, isoforma de PKC, e seu uso em particular em transplantação.
BRPI0506939-4A 2004-01-19 2005-01-19 derivados de indolilmaleimida como inibidores de pkc BRPI0506939A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0401090A GB0401090D0 (en) 2004-01-19 2004-01-19 Organic compounds
GB0401089A GB0401089D0 (en) 2004-01-19 2004-01-19 Organic compounds
PCT/EP2005/000502 WO2005068455A1 (en) 2004-01-19 2005-01-19 Indolylmaleimde derivatives as pkc inhibitors

Publications (1)

Publication Number Publication Date
BRPI0506939A true BRPI0506939A (pt) 2007-06-12

Family

ID=34796827

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0506939-4A BRPI0506939A (pt) 2004-01-19 2005-01-19 derivados de indolilmaleimida como inibidores de pkc
BRPI0506958-0A BRPI0506958A (pt) 2004-01-19 2005-01-19 derivados de indolilmaleimida

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0506958-0A BRPI0506958A (pt) 2004-01-19 2005-01-19 derivados de indolilmaleimida

Country Status (15)

Country Link
US (2) US7691861B2 (pt)
EP (3) EP1709030B1 (pt)
JP (2) JP2007518730A (pt)
CN (1) CN101933926A (pt)
AT (1) ATE391127T1 (pt)
AU (3) AU2005205183B2 (pt)
BR (2) BRPI0506939A (pt)
CA (2) CA2552738A1 (pt)
DE (1) DE602005005787T2 (pt)
ES (2) ES2303218T3 (pt)
MX (1) MXPA06008158A (pt)
PL (1) PL1709030T3 (pt)
PT (1) PT1709030E (pt)
RU (2) RU2373201C2 (pt)
WO (2) WO2005068454A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006268908A1 (en) * 2005-07-11 2007-01-18 Novartis Ag Indolylmaleimide derivatives
US20070148628A1 (en) * 2005-12-09 2007-06-28 Philadelphia College Of Osteopathic Medicine Organ preservation and/or perfusion
CA2632777C (en) * 2005-12-09 2019-08-20 Philadelphia College Of Osteopathic Medicine Organ preservation and/or perfusion
JP2010512335A (ja) * 2006-12-07 2010-04-22 ノバルティス アーゲー 移植におけるｐｋｃ阻害剤の使用
CN102838610B (zh) * 2012-08-28 2014-09-10 吕叶叶 双吲哚二氧杂双环辛二酮
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
AU2016302940B2 (en) 2015-07-31 2021-02-04 The Johns Hopkins University Prodrugs of glutamine analogs
CA2994165A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
CA3052283A1 (en) 2017-02-01 2018-08-09 The Johns Hopkins University Prodrugs of glutamine analogs
CN110551103B (zh) * 2018-05-30 2022-08-23 北京大学深圳研究生院 一种jak3选择性抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36736A (en) * 1862-10-21 Improvement in curry-combs
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
NO308798B1 (no) * 1993-12-07 2000-10-30 Lilly Co Eli Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
AU2002221810B2 (en) 2000-11-07 2005-06-23 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
BE1014306A6 (fr) 2001-07-19 2003-08-05 Project 21C Dispositif de stationnement d'un cycle avec antivol.
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
DE60323749D1 (de) * 2002-06-05 2008-11-06 Janssen Pharmaceutica Nv Substituierte pyrroline als kinase inhibitoren

Also Published As

Publication number Publication date
EP2270001A1 (en) 2011-01-05
AU2005205182A1 (en) 2005-07-28
ES2402298T3 (es) 2013-04-30
DE602005005787D1 (de) 2008-05-15
AU2009227818A1 (en) 2009-11-05
EP1745037A1 (en) 2007-01-24
CA2552740A1 (en) 2005-07-28
AU2005205183A1 (en) 2005-07-28
RU2006129891A (ru) 2008-02-27
BRPI0506958A (pt) 2007-07-24
JP4914223B2 (ja) 2012-04-11
US7691861B2 (en) 2010-04-06
RU2372348C2 (ru) 2009-11-10
WO2005068455A1 (en) 2005-07-28
EP1709030A1 (en) 2006-10-11
WO2005068454A1 (en) 2005-07-28
DE602005005787T2 (de) 2009-04-30
JP2007518730A (ja) 2007-07-12
RU2373201C2 (ru) 2009-11-20
PT1709030E (pt) 2008-07-01
AU2005205182B2 (en) 2009-07-16
EP1745037B1 (en) 2013-01-02
US7648989B2 (en) 2010-01-19
ATE391127T1 (de) 2008-04-15
US20080242675A1 (en) 2008-10-02
EP1709030B1 (en) 2008-04-02
MXPA06008158A (es) 2007-01-30
US20080234494A1 (en) 2008-09-25
RU2006129890A (ru) 2008-02-27
ES2303218T3 (es) 2008-08-01
AU2005205183B2 (en) 2009-08-06
JP2007518731A (ja) 2007-07-12
CN101933926A (zh) 2011-01-05
CA2552738A1 (en) 2005-07-28
PL1709030T3 (pl) 2008-09-30

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
EP1723122A4 (en) Dimeric small molecule potentiators of apoptosis
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
DK1960370T3 (da) Pyridazinonderivater til tumorbehandling
BRPI0818672A2 (pt) 2&#39;-fluor-2&#39;-desoxitetra-hidrouridinas como inibidores da citidina desaminase
DE602005018509D1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
EP1807077A4 (en) INHIBITORS OF C-FMS KINASE
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
HRP20080377B1 (hr) ANTAGONISTI AKTIVIN-ActRIIa I PRIMJENE ZA STIMULACIJU RASTA KOSTI
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
BRPI0506939A (pt) derivados de indolilmaleimida como inibidores de pkc
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
CR9677A (es) Derivados de pirrolo(2,3-b) piridina como inhibidores de proteina cinasa
EP1853358A4 (en) EXTINGUISHING FOAM CONCENTRATE
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
DK1938839T3 (da) Oftalmiske sammensætninger af parasympatiske stimulanter og anti-inflammatoriske midler til anvendelse i behandlingen af presbyopi
BRPI0812865A2 (pt) Derivados de 6-anilinopurina substituída como inibidores de citoquinina oxidase/desidrogenase e preparações contendo esses derivados.
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602005009255D1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
BRPI0512547A (pt) pirimidinas
EA200701306A1 (ru) Лиофилизация виросом

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.